Physician profile
Buffy J Cook
NPI 1063406114
$3,654.60
in general payments reported to CMS, 2019-2025
23 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.69 · 2022: $492 · 2023: $847 · 2024: $982 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.24 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,045.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $478.68 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $459.41 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $366.80 | 2022-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $167.73 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $147.28 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $128.81 | 2022 | |
| Exact Sciences Corporation | $120.39 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.26 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $115.10 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $110.56 | 2025 | Freestyle Libre 3 |
| Intuitive Surgical, INC. | $90.59 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.29 | 2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $55.69 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.50 | 2023 | Tradjenta, Synjardy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.92 | 2023 | Veozah |
| Boston Scientific Corporation | $19.48 | 2025 | Watchman Flx |
| Nevro Corp. | $18.05 | 2023 | Senza |
| Phathom Pharmaceuticals, INC. | $15.61 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $15.01 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.40 | 2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buffy Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.